Table 4 Antibiotics for treating patients with IAIs based upon susceptibility [253]
| Antibiotic | Enterococci | Ampicillin-resistant enterococci | Vancomycin-resistantenterococci | Enterobacteriaceae | ESBL-producing Enterobactericeae | Pseudomonas aeruginosa | Anaerobic gram-negative bacilli |
|---|---|---|---|---|---|---|---|
| Penicillins/beta-lactamase inhibitors | |||||||
| Amoxicillin/clavulanate | + | − | − | + | − | − | + |
| Ampicillin/sulbactam | + | − | − | + | − | − | +/− |
| Piperacillin/tazobactam | + | − | − | + | +/− | + | + |
| Carbapenems | |||||||
| Ertapenem | − | − | − | + | + | − | + |
| Imipenem/cilastatin | +/−a | − | − | + | + | + | + |
| Meropenem | − | − | − | + | + | + | + |
| Doripenem | − | − | − | + | + | + | + |
| Fluoroquinolones | |||||||
| Ciprofloxacin | − | − | − | + | − | +b | − |
| −−Levofloxacin | +/− | − | − | + | − | +/− | − |
| Moxifloxacin | +/− | − | − | + | − | − | +/− |
| Cephalosporins | |||||||
| Ceftriaxone | − | − | − | + | − | − | − |
| Ceftazidime | − | − | − | + | − | + | − |
| Cefepime | − | − | − | + | +/− | + | − |
| Ceftozolane/tazobactam | − | − | − | + | + | + | − |
| Ceftazidime/avibactam | − | − | − | + | + | + | − |
| Aminoglycosides | |||||||
| Amikacin | + | + | + | − | |||
| Gentamicin | + | + | + | − | |||
| Glycylcyclines | |||||||
| Tigecycline | + | + | + | +c | + | − | + |
| 5-Nitroimidazole | |||||||
| Metronidazole | + | ||||||
| Polymixyn | |||||||
|
Colistimethate (Colistin) | − | − | − | +d | + | + | − |
| Glycopeptides | |||||||
| Teicoplanin | + | + | − | − | − | − | − |
| Vancomycin | + | + | − | − | − | − | − |
| Oxazolidines | |||||||
| Linezolid | + | + | + | − | − | − | − |